EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing

Sveinung Wergeland Sørbye, Bente Marie Falang, Mona Antonsen, Elin Richardsen

Pathogens · 20.11.2026 · 15 (11) · 1221

DOI: 10.3390/pathogens15111221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 20.11.2026. Verfasst von Sveinung Wergeland Sørbye und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We compared surveillance strategies in a retrospective regional cohort of 2136 women who underwent conisation for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) in 2016–2020. Using results from the first eligible visit 90–548 days after treatment, we evaluated cytology, human papillomavirus (HPV) DNA testing and HPV16/18/45 E6/E7 messenger RNA (mRNA) testing, individually and in combination. We also evaluated an exploratory referral strategy adapted from the Addressing the Need for Advanced HPV Diagnostics (ATHENA) study. Histological outcomes were ascertained through 2025. Median available administrative follow-up was 7.24 years. CIN3+ (CIN3, adenocarcinoma in situ or invasive cervical cancer) was recorded in 74 women (3.5%). For CIN3+, HPV DNA testing had 93.2% sensitivity, 78.0% specificity and 24.4% positivity. Adding mRNA positivity to high-grade+ cytology increased CIN3+ sensitivity from 60.8% to 82.4%, with 92.1% specificity and 10.4% test positivity. Combining ASC-US+ cytology with mRNA positivity achieved the highest observed CIN3+ sensitivity (95.9%), with 73.5% specificity. The ATHENA-derived strategy achieved 90.5% sensitivity and 83.1% specificity, with 19.4% classified as referral-positive. Among women with equivocal or low-grade cytology, CIN3+ was recorded in 18.6% with positive mRNA and 2.5% with negative mRNA. Cytology and genotype-specific mRNA co-testing may support risk stratification after conisation. Prospective evaluation is needed to establish safe surveillance intervals.

Zitieren

APA

Sørbye, S. W., Falang, B. M., Antonsen, M., & Richardsen, E. (2026). Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing. Pathogens, 15(11), 1221. https://doi.org/10.3390/pathogens15111221

Vancouver

Sørbye SW, Falang BM, Antonsen M, Richardsen E. Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing. Pathogens. 2026;15(11):1221. doi:10.3390/pathogens15111221

BibTeX
@article{Srbye2026,
  author = {Sørbye, Sveinung Wergeland and Falang, Bente Marie and Antonsen, Mona and Richardsen, Elin},
  title = {Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1221},
  doi = {10.3390/pathogens15111221}
}
Kostenlos starten →